Takeda (NYSE: TAK) Chief Medical Officer granted 17,554 RSUs vesting from 2027

Rhea-AI Filing Summary

Farajallah Awny Samaan Botros reported acquisition or exercise transactions in this Form 4 filing.

Takeda Pharmaceutical Chief Medical Officer Awny Samaan Farajallah received an equity grant of 17,554 American Depositary Shares as a compensation award. The award is in the form of restricted stock units, each convertible into one ADS, and vests in three equal annual installments starting on July 1, 2027. Following this grant, his direct holdings increase to 130,183 ADSs, reinforcing equity-based alignment with shareholders through a long-term vesting schedule.

Insights

Equity Compensation Analyst

Routine RSU grant to Takeda’s CMO increases long-term equity stake.

The filing shows Chief Medical Officer Awny Samaan Farajallah received 17,554 restricted stock units, each settling into one American Depositary Share. This is compensation-related, at no purchase price, not an open-market buy.

The RSUs vest in three equal annual installments beginning on July 1, 2027, creating a multi-year retention and performance incentive. After the grant, his direct holdings rise to 130,183 ADSs, indicating a meaningful but routine executive equity position.

Because the transaction is a standard grant rather than a discretionary market purchase or sale, its informational value for near-term stock expectations is limited. Future company filings may provide additional detail on broader executive compensation trends.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Farajallah Awny Samaan Botros

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	American Depositary Shares	17,554	$0.00	--

Holdings After Transaction: American Depositary Shares — 130,183 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 17,554 shares Transaction price per share: $0.0000 per share Holdings after transaction: 130,183 shares +2 more

5 metrics

RSU grant size 17,554 shares Restricted stock units awarded to CMO

Transaction price per share $0.0000 per share Equity compensation grant, no cash paid

Holdings after transaction 130,183 shares American Depositary Shares directly held post-grant

Vesting start date July 1, 2027 First of three annual RSU vesting installments

Transaction code A (grant/award acquisition) Indicates compensation-related share acquisition

Key Terms

American Depositary Shares, restricted stock units, RSUs, vest, +1 more

5 terms

American Depositary Shares financial

"security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock units financial

"Represents an award of restricted stock units (RSUs)."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one American Depositary Share."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"The RSUs vest in three equal annual installments beginning on July 1, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition regulatory

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 06:06 PM Accepted by SEC EDGAR 07/06/2026 - 06:06 PM Learn about SEC filing dates

FAQ

What did Takeda (TAK) disclose in this Form 4 for its Chief Medical Officer?

Takeda reported that Chief Medical Officer Awny Samaan Farajallah received a grant of 17,554 restricted stock units, each tied to one American Depositary Share. This is an equity compensation award, not an open-market stock purchase or sale by the executive.

How many Takeda (TAK) shares were granted to the CMO in this transaction?

The Chief Medical Officer was granted 17,554 restricted stock units linked to Takeda American Depositary Shares. Each RSU represents a contingent right to receive one ADS, increasing his direct equity-based compensation position upon vesting over time, subject to the stated schedule.

What is the vesting schedule for the new Takeda (TAK) RSU award?

The restricted stock units vest in three equal annual installments beginning on July 1, 2027. This structure spreads the benefit over several years, encouraging long-term retention and alignment of the Chief Medical Officer’s interests with those of Takeda shareholders.

Did the Takeda (TAK) Chief Medical Officer pay anything for these RSUs?

No cash purchase was involved; the Form 4 shows a transaction price of $0.0000 per American Depositary Share. The 17,554 RSUs were granted as part of compensation, consistent with a non-cash equity award rather than an open-market acquisition of Takeda shares.

What are the Chief Medical Officer’s Takeda (TAK) holdings after this RSU grant?

After the award, the Form 4 reports that the Chief Medical Officer directly holds 130,183 American Depositary Shares. This total reflects his position following the 17,554-unit grant, providing context for the size of the new award relative to his existing Takeda equity holdings.

Are these Takeda (TAK) RSUs considered a buy or sell transaction by the insider?

They are classified as an acquisition through a grant, coded as an award transaction rather than a market buy. The Form 4 describes it as a grant or other acquisition of 17,554 restricted stock units, received as compensation instead of a discretionary stock market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farajallah Awny Samaan Botros

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	07/01/2026		A(1)		17,554	A	$0	130,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027.

Remarks:

	/s/ Kate Huleatt, by power of attorney, for Awny S. Farajallah	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)